In contrast, anti-Scg3 hAb was not only bereft of adverse side effects but also conferred therapeutic benefits in OIR mice by supporting revascularization and improving retinal function, which was consistent with a safer and more effective option for ROP treatment. This evidence concerns the gene SCG3 and retinopathy of prematurity.